• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Systemic availability of o,p'-DDD in normal dogs, fasted and fed, and in dogs with hyperadrenocorticism.

作者信息

Watson A D, Rijnberk A, Moolenaar A J

机构信息

Small Animal Clinic, State University of Utrecht, The Netherlands.

出版信息

Res Vet Sci. 1987 Sep;43(2):160-5.

PMID:3685628
Abstract

The systemic availability of o,p'-DDD was studied in 12 normal dogs and seven dogs with pituitary-dependent hyperadrenocorticism (PDH). The drug was given by mouth at 50 mg kg-1 and plasma o,p'-DDD concentrations were determined by gas-liquid chromatography. First, six normal dogs were given the drug three times at intervals of one week in a Latin square pattern. Systemic drug availability was found to be very poor from intact tablets in fasted dogs, better with pure drug dissolved in maize oil given by stomach tube, and best with ground tablets mixed in oil poured on dog food. Then six normal dogs and five with PDH were given one dose of o,p'-DDD as intact tablets in dog food. Systemic drug availability was good in the normal animals and, for unknown reasons, better in dogs with PDH. The half-time of elimination was shorter in dogs with PDH than in normal ones. There was evidence of a gradual rise in plasma o,p'-DDD concentrations in seven dogs with PDH treated with 25 mg kg-1 every 12 hours for 14 or 20 days. The interaction between food and o,p'-DDD probably contributes to the variation in clinical response of dogs treated with the drug. The efficiency of therapy with o,p'-DDD should be improved considerably by administering the drug with food.

摘要

相似文献

1
Systemic availability of o,p'-DDD in normal dogs, fasted and fed, and in dogs with hyperadrenocorticism.
Res Vet Sci. 1987 Sep;43(2):160-5.
2
Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).在使用米托坦(邻,对'-滴滴滴)进行诱导治疗期间,利用尿皮质醇与肌酐比值监测垂体依赖性肾上腺皮质功能亢进症犬。
Am J Vet Res. 1998 Mar;59(3):258-61.
3
Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p'-DDD (mitotane) in Minipigs.肾上腺皮质溶解化合物3-甲基磺酰基-DDE和邻,对'-滴滴滴(米托坦)在小型猪体内的药代动力学
Cancer Chemother Pharmacol. 2008 Feb;61(2):267-74. doi: 10.1007/s00280-007-0468-x. Epub 2007 Apr 12.
4
Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.米托坦治疗犬肾上腺肿瘤与垂体依赖性肾上腺皮质功能亢进的比较。
J Am Vet Med Assoc. 1992 Jun 1;200(11):1642-7.
5
Hypoadrenocorticism following therapy with o,p-DDD for hyperadrenocorticism in four dogs.
J Am Vet Med Assoc. 1982 Mar 15;180(6):638-41.
6
Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism.患有肾上腺皮质功能亢进症的犬只对酮康唑给药的血浆皮质醇反应。
J Am Vet Med Assoc. 1990 Jul 1;197(1):71-8.
7
Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism.米托坦(邻,对'-滴滴滴)治疗200只垂体依赖性肾上腺皮质功能亢进犬。
J Vet Intern Med. 1991 May-Jun;5(3):182-90. doi: 10.1111/j.1939-1676.1991.tb00945.x.
8
Interindividual differences in o,p'-DDD enantiomer kinetics examined in Göttingen minipigs.在哥廷根小型猪中研究的邻,对'-滴滴滴对映体动力学的个体间差异。
Chemosphere. 2009 Jun;76(2):167-72. doi: 10.1016/j.chemosphere.2009.03.050. Epub 2009 Apr 25.
9
Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.垂体依赖性肾上腺皮质增生症的药物治疗:米托坦与曲洛司坦的比较
Clin Tech Small Anim Pract. 2007 Feb;22(1):18-25. doi: 10.1053/j.ctsap.2007.02.003.
10
Medical treatment of canine hyperadrenocorticoidism with o,p'-DDD.
Cornell Vet. 1973 Oct;63(4):646-65.

引用本文的文献

1
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.米托坦的挑战性药代动力学:一种需要新包装的老药。
Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):575-593. doi: 10.1007/s13318-021-00700-5. Epub 2021 Jul 21.
2
Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?米托坦在肾上腺皮质癌患者中的群体药代动力学建模与模拟:一种针对所有患者在三个月时达到目标的个体化给药方案?
Pharmaceutics. 2019 Oct 31;11(11):566. doi: 10.3390/pharmaceutics11110566.
3
Veterinary Compounding: Regulation, Challenges, and Resources.
兽医配制药剂:监管、挑战与资源
Pharmaceutics. 2017 Jan 10;9(1):5. doi: 10.3390/pharmaceutics9010005.